Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

484
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
484
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

1.9K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.9K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

503
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
503
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

650
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
650

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Surgical Versus Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis: 1-Year Clinical Outcomes in Patients Aged 65 Years and Older.

Journal of the American Heart Association·2026
Same author

Sex Differences in Long COVID Prevalence Over One year After the Acute Phase, and Related Risk Factors. The GINA-COVID Cohort Study.

International journal of women's health·2026
Same author

Single-device large-bore thrombectomy for combined pulmonary embolism and iliac vein thrombosis treatment.

The Journal of invasive cardiology·2026
Same author

Different Types of Aortic Valve Stenosis in Patients Undergoing Transcatheter Aortic Valve Replacement.

Structural heart : the journal of the Heart Team·2026
Same author

Cardiovascular Prognosis in Stable Patients with Cardiac Amyloidosis: A Novel and Simple Risk Score.

Journal of clinical medicine·2026
Same author

Predictive value of the combined use of NT-proBNP and CA125 biomarkers in a cohort of 138 patients with heart failure with reduced ejection fraction.

Medicina clinica·2026

Related Experiment Video

Updated: Apr 21, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

751

Ultimaster TANSEI Stent in Complex Coronary Lesions: The EPIC08 TANSEI COMPLEX Study.

Ricardo Palma-Carbajal1, Yassin Belahnech1, José María de la Torre Hernández2

  • 1Department of Cardiology, Hospital Universitario Vall d'Hebron Barcelona, Spain.

Interventional Cardiology (London, England)
|April 20, 2026
PubMed
Summary

The Ultimaster TANSEI drug-eluting stent (DES) demonstrated acceptable safety and efficacy in complex coronary lesions. Long lesions (>35 mm) were associated with significantly higher risks for adverse events and mortality.

Keywords:
Clinical studycomplex coronary lesionsdrug-eluting stentoutcomespercutaneous coronary intervention

Related Experiment Videos

Last Updated: Apr 21, 2026

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
06:59

Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis

Published on: August 26, 2025

751

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Biomedical Engineering

Background:

  • Percutaneous coronary intervention (PCI) is increasingly used for complex coronary anatomy.
  • The Ultimaster TANSEI drug-eluting stent (DES) was developed for challenging lesions.

Purpose of the Study:

  • To evaluate the safety and efficacy of the Ultimaster TANSEI DES in patients with complex coronary lesions.
  • To assess device-oriented composite endpoint (DoCE) and patient-oriented composite endpoint (PoCE) at 1-year follow-up.

Main Methods:

  • A prospective, single-arm, multicentre registry of 501 patients with 591 complex lesions.
  • Patients were treated with Ultimaster TANSEI DES and followed for 1 year.
  • Primary endpoint: DoCE (cardiac death, target-vessel MI, TVR, stent thrombosis). Secondary endpoint: PoCE (all-cause death, any MI, any revascularisation).

Main Results:

  • At 1 year, DoCE incidence was 3.23 per 100 person-years and PoCE incidence was 5.04 per 100 person-years.
  • Complex lesion subsets included left main (11%), bifurcations (43.9%), small vessels (40.7%), and long lesions (34.3%).
  • Long lesions (>35 mm) showed significantly higher risks: DoCE RR 4.22, PoCE RR 4.93, mortality RR 4.79, and TVR RR 17.60.

Conclusions:

  • The Ultimaster TANSEI DES is safe and effective for complex coronary lesions.
  • Long lesions represent a high-risk subgroup requiring careful consideration.
  • Further research may explore optimized strategies for treating long complex lesions.